Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy.
Benevento
Joseph D
JD
University of Chicago, AMBH S206, 5841 S Maryland Ave, Chicago, IL 60637, USA.
Jager
Rama D
RD
Noble
A Gwendolyn
AG
Latkany
Paul
P
Mieler
William F
WF
Sautter
Mari
M
Meyers
Sanford
S
Mets
Marilyn
M
Grassi
Michael A
MA
Rabiah
Peter
P
Boyer
Kenneth
K
Swisher
Charles
C
McLeod
Rima
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002648:Child; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D011739:Pyrimethamine / Q000627:therapeutic use; D000069579:Ranibizumab; D012166:Retinal Hemorrhage / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology; D013411:Sulfadiazine / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D014126:Toxoplasmosis, Ocular / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000981:Antiprotozoal Agents; D013411:Sulfadiazine; D002955:Leucovorin; D011739:Pyrimethamine; D000069579:Ranibizumab